SD - Compugen reports updated COM701 data from Phase 1 study at ASCO21

Compugen (CGEN) presents updated data from its Phase 1 study of COM701 as a monotherapy, and in combination study with Opdivo (nivolumab) at the ASCO 2021 Annual Meeting. Data highlights are with a cut-off of April 15 2021.COM701 and Opdivo combination: In 15 evaluable patients, COM701 in combination with Opdivo was well-tolerated with no reported dose-limiting toxicities.The disease control rate ((DCR)) was 66.7% (N=10) with best responses of complete response ((CR)) 6.7% (N=1), partial response ((PR)) 6.7% (N=1) and stable disease ((SD)) 53.3% (N=8).COM701 monotherapy arm: Overall 36 patients enrolled.The DCR was 47.2% (N=17) with best responses of PR 2.7% and SD 44.4% (N=16).Peripheral blood assessment showed immune activation as measured by immune cell proliferation and IFN? induction prior to tumor shrinkage.Durable antitumor activity in pretreated population:Durable responses to treatment (CR, PR or SD ? 6 months) in 10/51 (19%) patients.Best responses of CR, PR, or SD were observed in 11/21 (52%)

For further details see:

Compugen reports updated COM701 data from Phase 1 study at ASCO21